6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2022-08-17), Moderna's 6-1 Month Momentum % is 14.04%.
The industry rank for Moderna's 6-1 Month Momentum % or its related term are showing as below:
MRNA's 6-1 Month Momentum % is ranked better than 85.98% of 1541
companies
in the Biotechnology industry
Industry Median: -23.53
vs MRNA: 14.04
Competitive Comparison
For the Biotechnology subindustry, Moderna's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Moderna's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Moderna's 6-1 Month Momentum % falls into.
Moderna (NAS:MRNA) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (NAS:MRNA) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Moderna 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Moderna's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
9.96(5.93%) Volume: 5,500,496 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:MRNA has been successfully added to your 
